{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:05:54Z","timestamp":1791137154964,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2023-0102"],"award-info":[{"award-number":["6-2023-0102"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jmii.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:08:24Z","timestamp":1744135704000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aminoglycoside susceptibility and treatment outcomes in Mycobacterium avium complex pulmonary disease"],"prefix":"10.1016","volume":"58","author":[{"given":"Shihwan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Sung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-1491","authenticated-orcid":false,"given":"Youngmok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.03.018_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.018_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib3","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2025.03.018_bib4","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jmii.2025.03.018_bib5","series-title":"Drug Susceptibility Testing of Nontuberculous Mycobacteria","author":"van Ingen","year":"2019"},{"key":"10.1016\/j.jmii.2025.03.018_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10156-006-0457-8","article-title":"Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates","volume":"12","author":"Kobashi","year":"2006","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10156-011-0351-x","article-title":"Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period","volume":"18","author":"Kobashi","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017","article-title":"Mycobacterium avium complex disease","volume":"5","author":"Daley","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jmii.2025.03.018_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02027-21","article-title":"Relationship between resistance to ethambutol and rifampin and clinical outcomes in Mycobacterium avium complex pulmonary disease","volume":"66","author":"Moon","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib10","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2025.03.018_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (convert). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib15","series-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","year":"2018"},{"key":"10.1016\/j.jmii.2025.03.018_bib16","series-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes","year":"2018"},{"key":"10.1016\/j.jmii.2025.03.018_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2025.03.018_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202004-1418OC","article-title":"BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease","volume":"203","author":"Kim","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.03.018_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","article-title":"The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases","volume":"17","author":"Yagi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.018_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin inhalation as Salvage therapy for refractory nontuberculous mycobacterial lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium complex lung disease with a Little help from my friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jmii.2025.03.018_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00491-18","article-title":"In vitro MIC values of rifampin and ethambutol and treatment outcome in Mycobacterium avium complex lung disease","volume":"62","author":"Kwon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib23","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jmii.2025.03.018_bib24","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jmii.2025.03.018_bib26","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jmii.2025.03.018_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00466-2021","article-title":"Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study","volume":"7","author":"Zweijpfenning","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jmii.2025.03.018_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jmii.2025.03.018_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4046\/trd.2023.0120","article-title":"Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease","volume":"87","author":"Kim","year":"2024","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.jmii.2025.03.018_bib30","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.03.018_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:51:38Z","timestamp":1762555898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1684118225000805"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.03.018","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminoglycoside susceptibility and treatment outcomes in Mycobacterium avium complex pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}